Lead Candidate PIN Pharma is developing PIN-2 for oncology, with preclinical synergy with cytotoxic therapies and checkpoint inhibitors, and a first-in-human proof-of-concept in solid tumors measuring key immune markers. This creates opportunities for co-development or licensing discussions with immuno-oncology players and for biomarker-driven trial design.

Innate Immunity Edge The company’s platform targets the innate immune system to drive adaptive responses, offering a potential first-in-class mechanism that could appeal to pharma seeking novel immuno-oncology approaches. This supports partnerships around platform licensing or research collaborations across oncology, autoimmunity, and neurodegeneration.

Outsourcing Model As a venture-backed, small team with limited internal capacity, PIN Pharma will rely on CROs/CDMOs and external partners to advance PIN-2 and related programs. This presents sales opportunities for early-phase development services, manufacturing support, and strategic co-development arrangements.

Funding and Partnerships With venture backing and modest revenue, PIN Pharma is positioned for milestone-driven partnerships and potential out-licensing opportunities that align with its early-stage pipeline and capital needs. This can attract big pharma interest in co-development or licensing deals.

Location Advantage Based in New York City, the company sits in a dense biotech ecosystem with access to major pharma hubs, clinical networks, and talent. BD efforts can focus on US-based immuno-oncology and neurology players for near-term collaborations and biomarker partnerships.